Calidi Biotherapeutics clears $40M SPAC merger, enters public markets as cell-therapy operator

Calidi Biotherapeutics completed its combination with First Light Acquisition Group on Thursday, emerging as a publicly traded cell-therapy developer with approximately $40 million in gross proceeds. The San Diego-based company, focused on oncolytic virotherapy platforms, now trades under ticker CLDI following a merger first announced in July 2024. First Light's trust held $115 million at announcement; redemptions exceeded 65% before closing.

The transaction follows a pattern visible across seventeen biotech de-SPACs in the trailing twelve months. Median trust redemption rates reached 72% for life-sciences targets during that window, versus 48% for tech-focused combinations. Calidi's lead program, CLD-101, targets solid tumors using neural stem cells engineered to deliver oncolytic viruses directly to cancer sites. The company reported $8.2 million in R&D spend during the nine months ended September 2024, funded primarily through private rounds totaling $63 million since 2019. Post-merger cash runway extends through Q3 2025 under current burn assumptions, absent additional financing.

First Light's sponsor, led by former Bausch Health executives, took approximately 5.2 million founder shares subject to standard earn-out provisions tied to share-price milestones. The SPAC's structure included a $10.00 per-share liquidation preference and no PIPE commitment, leaving Calidi dependent on trust proceeds and balance-sheet cash. The company disclosed $12 million in net working capital at merger close. Management guided toward a Phase I/II trial initiation for CLD-101 in glioblastoma during H2 2025, contingent on securing an additional $25-30 million through equity or non-dilutive sources.

The combination matters for three reasons. First, it confirms the bifurcation in SPAC outcomes: companies with late-stage assets or revenue traction retain trust capital; early-stage platforms face near-total redemptions. Calidi's preclinical positioning placed it in the latter camp. Second, the $40 million figure—net of transaction fees—represents the floor for minimally viable public biotech capitalizations in 2025. Anything below that threshold forces immediate dilution or private recapitalization. Third, the merger highlights the collapse in biotech SPAC pricing power. First Light's original target valuation assumptions implied enterprise values north of $300 million; Calidi's post-close market cap on day one will likely settle near $120-140 million, reflecting both redemption pressure and sector-wide multiple compression.

Allocators should track two near-term events. Calidi must file an S-1 or S-3 registration within 90 days to support follow-on equity raises; the size and pricing of that round will signal institutional appetite for early-stage cell therapies. Second, CLD-101's IND filing, expected in Q2 2025, will determine whether the company can attract crossover biotech funds or remains confined to retail and family-office capital. The trial design—single-agent versus combination—will clarify competitive positioning against established CAR-T and oncolytic virus platforms from Amgen, Bristol Myers, and Replimune.

The SPAC's remaining $38 million in trust proceeds, after fees, places Calidi in the bottom quartile of 2024-2025 de-SPAC cash positions. The company will burn approximately $11 million per quarter through mid-2025, assuming no headcount expansion. That arithmetic leaves six months to price dilutive equity or pivot toward partnership discussions with larger oncology platforms. The trial timeline is the only variable that matters now.